Arcutis Biotherapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGArcutis Biotherapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 62), indicating performance broadly in line with the market. Earnings growth of 55% provides fundamental context to the price action. Investors should exercise caution due to high volatility (58% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $22.99 | +15.99% | ABOVE |
| 50 SMA | $22.80 | +16.90% | ABOVE |
| 100 SMA | $23.75 | +12.25% | ABOVE |
| 150 SMA | $25.31 | +5.34% | ABOVE |
| 200 SMA | $24.05 | +10.84% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARQT in an uptrend right now?
ARQT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ARQT overbought or oversold?
ARQT's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ARQT outperforming the market?
ARQT has a Relative Strength (RS) Rating of 62 out of 99. ARQT is performing about average compared to the market.
Where is ARQT in its 52-week range?
ARQT is trading at $26.66, which is 84% of its 52-week high ($31.77) and 73% above its 52-week low ($13.06).
How volatile is ARQT?
ARQT has a Beta of 1.46 and 52-week volatility of 58%. It's more volatile than the S&P 500 - expect bigger swings.